
Delays could harm older Americans, interest group states.
In what could presage a radical reshuffling of drug pricing and distribution, the insurer is dropping CVS Caremark as its PBM.
Guidelines expected to assist companies with EPCIS-based sTI/TS data exchange as they prepare to meet November DSCSA deadlines.
The act is currently set to go into effect in just over three months.
H1 Mobile to offer latest information and research in multiple fields.
Analysis requested by PhRMA indicates that these facilities charge anywhere from two to seven times what they originally paid.
The company anticipates that the offering will help maximize life sciences brands’ commercial potential.
Experienced pharma exec joins the business’ management board.
Company will focus on its managed access services.
CDMO makes four new executive appointments.
Citing growth as contributing factor, SaaS provider plans on relocating to a biopharma hub in Waltham, MA.
Strategy includes a layoff of nearly 400 employees.
Karin Van Den Brekel, Niall Walsh hired to manage EMEA and Ireland respectively.
The company will occupy approximately 62,000 square feet of the new building.
The plant— dedicated to cell and gene therapy development—welcomes additional warehouse space, and aims to meet commercial needs.
Stephanie Smith Cooney joins PBM business to further develop partnerships, especially with independent pharmacists in local communities.
Offering provides assistance through the post-approval lifecycle of drugs.
The finished product, company says, can assist with the medical supply chain’s vaccine distribution process.
Latest IATA stats for the month show that it was only 2.4% below pre-pandemic levels.
Company is seeking monetary damages from the alleged violation.
Portfolio features 13 brands spanning six therapeutic areas, mainly revolving around pain management.
The agreement provides Scripta patients with another option when purchasing medication.
CDMO’s Taoyuan City plant is set to provide customers with products ranging from emulsions to gels.
As a result, the parties will work together to advise pharma clients on subject matters pertaining to strategy and planning, market access, policy analysis, and more. .
The experienced manager will head the company’s US plant.
Total deal expected to be worth approximately $7.3 billion.
The executive joins the logistics provider with over two decades of relevant experience.
AI, ML-based deal builds on the parties’ existing relationship.
Parties are expected to be fully integrated by the second half of 2024.
Product is expected to maintain a steady temperature setting between 65°F (18°C) and 80°F (27°C).